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Background/aim: One of the most important components of treatment for diabetic patients is diet and healthy nutrition therapy.
Calorie restriction is effective and without cost increases its appeal for both patients and physicians. Unfortunately, continuous calorie
restriction is a difficult method. For this reason, alternative calorie restriction methods, such as intermittent fasting (IF), have been
investigated by some researchers.
Materials and methods: IF refers to a wide range of diet programmes covering periods of eating and fasting, which vary according to
the different regimens. In this article, first, some general information will enable us to understand the concept of IF, and then scientific
evidence with respect to IF applications in diabetes will be discussed in detail. Thereafter our clinical experience will be summarised,
finally, the author will try to answer the question “are the IF applications beneficial or harmful for diabetic patients?”
Results: Considering animal studies, epidemiological studies, pilot studies, clinical experiences and a small number of randomized
controlled trials conducted so far, it seems possible to say that the beneficial effects of IF for diabetes patients are greater than potential
harms. However, there are not yet enough studies with a high level of evidence to recommend IF as a routine part of the treatment in
patients with diabetes.
Conclusion: It is necessary to show which IF regimen is safe and effective, how often and for how long, for diabetic patients. This seems
possible with well-designed randomized controlled trials focusing on long-term clinical outcomes and eliminating confounding factors.
This will make the answer clearer.
Key words: Calorie restriction, diet, glucose reduction, intermittent fasting, type 2 diabetes mellitus, weight loss

1. Introduction
The causal relationship between type 2 diabetes and
obesity is well known. In fact, this association has been
called a “diabesity” epidemic in recent years. The effect
of weight loss on blood glucose regulation and on many
metabolic events has been proven. There are also many
studies demonstrating its effects on the long-term course
of diabetes as well as complications [1,2]. Therefore, one of
the most important components of treatment for diabetic
patients is diet and healthy nutrition therapy. In recent
years, the search for alternative applications to limit calorie
intake has come to the fore when determining weight
loss strategies for patients with diabetes [1]. Because
continuous energy restriction application is a difficult
method, intermittent fasting (IF) has emerged as a method
which has been considered, researched and applied by
some authors. The most significant contribution to the
subject has been in the area of Ramadan fasting. The fact
that calorie restriction (CR) is effective and without cost

increases its appeal for both patients and physicians and/
or researchers.
In this article, first, some general information will
enable us to understand the concept of IF, and then scientific
evidence with respect to IF applications in diabetes will
be discussed in detail. Ramadan fasting is accepted as a
type of IF, but since it involves some differences in terms
of diurnal rhythm, changes in sleep patterns, eating times
and content, we will only discuss some general information
about Ramadan fasting, and Ramadan fasting-diabetes
studies will not be detailed. We published our book with
detailed information on Ramadan fasting and diabetes in
Turkey [4].
2. Intermittent fasting
Since almost all religions include the concept of fasting, IF
is a lifestyle that has been practiced since human existence
began. When we look at the modern medical literature, we
see that animal studies on IF started in the first half of the
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twentieth century [4, 5], and the first human studies with
IF were carried out at the beginning of the second half
of the century [6]. After the 1990s, IF became a popular
research topic.
Human beings have biological rhythms, many of these
physiological and behavioural rhythms being circadian
rhythms, following an approximately 24-h cycle. From
this point of view, nutrition also has timing, and this will
affect the eating/fasting periods. Ultimately, the metabolic
rhythm will be affected, and insulin sensitivity, glycaemic
control and weight balance will change. It has been shown
in animal studies that metabolic pathways are negatively
affected by irregular and disrupted meal programmes [7].
It is also known that metabolic disorders such as obesity,
insulin resistance and diabetes develop with disruptions
in eating/fasting cycles in gene disorders related to the
mechanisms of the circadian clock.
IF refers to a wide range of diet programmes covering
periods of eating and fasting, which vary according to the
different regimens. The fasting period is usually over 12 h.
During these periods, the person may be free to consume
calorie-free liquids such as water and tea, and while
calories are restricted in some regimens during eating
periods, in others, the person takes food as desired [5].
The expected effects of IF on the body and the metabolism
first occur during periods of fasting and continue as the
process progresses.
In the feeding model called intermittent energy
restriction, over a period of approximately 24 h, the person
receives 25%–40% of the energy to be taken daily, and
then there are periods of normal food intake; the timing
of these periods can differ. These are followed by energyconstrained time periods, with the two periods alternating
with each other [5]. Although this method is used in the
literature in the same sense as IF, there is no complete
fasting period in these regimens.
Table shows the intermittent nutrition models used
in animal experiments and human studies conducted
so far. Among these, the 16/8 diet and the 5:2 diet are
most commonly used in clinical studies and are the most
popular diet regimens applied in daily life.
Animal studies have found that IF has positive effects
on atherosclerosis [8], cognitive functions [9,10], the
immune system [11] and the metabolism [8,9] and that it
extends the lifespan [12,13]. There are also clinical trials,
weight loss of up to 8%–10% and significant improvements
in LDL-C, TG and CRP compared to the control group are
reported with IF. The opinion is that the cellular-molecular
effects which provide these metabolic changes occur
through three main pathways. Path 1: AMP-activated
protein kinase (AMPK) is activated as a result of the
increase of AMP with the decrease of intracellular ATP.
Path 2: Decreased circulating glucose and amino acids
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with fasting inhibit rapamycin (mTOR), the intracellular
energy sensor [14]. Path 3: Due to the need for energy,
glycolysis starts in the liver, with a fatty acid release
from adipose tissue [15]. Health is positively affected by
increasing autophagy and decreasing oxidative stress.
As clinical reflections of these processes, weight loss, a
decrease in insulin and blood glucose and a decrease in
blood pressure and serum lipid levels occur.
Mild side effects have been reported, especially in
the first days of IF application. These include weakness,
headache, muscle weakness, signs of dehydration,
hypoglycaemia, gout and peptic ulcer activation [1,16].
Situations such as anxiety and psychological stress were
also reported in some studies [17]. Although these
complaints are generally well tolerated, it is an appropriate
approach to avoid IF for patients, for example, with an
active peptic ulcer or upper GIS bleeding as well as for type
1 diabetes patients who can easily enter hypoglycaemia, for
the elderly, for those who cannot tolerate dehydration and
for those with malnutrition. Side effects such as postural
hypotension, gout and cardiac arrhythmia are mostly
associated with prolonged fasting-starvation and have not
been reported frequently in IF studies.
Clinical studies conducted with IF in people with
chronic diseases which cause comorbidity, such as
coronary artery disease, chronic kidney disease and
diabetes are almost absent. It should be kept in mind that
the harmful effects which may occur in such patients
may be more serious. More serious complications may
also occur with not eating adequately or with lacking
balance during periods of not fasting while applying IF,
for example, drinking less water, reducing protein and not
getting enough vitamins and minerals. Conditions such as
stroke due to severe dehydration or muscle wasting due to
excessive protein reduction can occur, especially in longterm and uncontrolled fasting regimens [16].
3. Intermittent fasting and diabetes-related animal
studies
The animal studies concerning IF and diabetes are mostly
focused on the effects of IF on pancreas beta cells, by using
either in vivo or in vitro techniques. Murine modelling
has generally been used in animal studies investigating
the effects of intermittent fasting on diabetes. For diabetes
modelling, some studies used a hypercaloric high-fat diet,
while some used leptin receptor knock-out mice [17].
Fast-mimicking diet (very low calorie diet), alternate day
fasting and time restricted feeding are generally applied
as an IF protocol [17]. The most important common
finding detected in animal models is the improvement of
beta cell function and insulin resistance without weight
loss. It has been shown that the lysosome-autophagy
and neurogenin 3 (Ngn3) pathway play a role in these
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Table. Frequently applied diet regimens for calorie restriction.
Fasting
duration
(hours)

Frequency

Characteristics-considerations

Daily calorie
restriction

Time-restricted feeding (16/8) 14–18

Every day

The person determines the hunger time
during the day

Voluntary

B2 regimen

16

Every day

2 main meals

Voluntary

Weekly one day fasting

24

Once a week (Every week)

Water only diet

Yes

Ramadan fasting

11–18

Voluntary
No any fluid or food (From dawn until
(e.g., during Ramadan or any
sunset)
time during the year)

Alternate day fasting

24

Every other day

Fasting day: 0%–25% of calorie
Feasting day: Ad libitum

5:2 diet

24

Twice a week

Fasting day: consecutive or
Yes
nonconsecutive Feasting days: ad libitum

Combination of IF and CR
(IFCR)

24

Variable

e.g., six days calorie restriction and one
day fasting

Yes

Intermittent VLCD

24

Variable

e.g., 1 day or 5 day VLCD

Yes

Kind of diet regimen
IF regimens

Voluntary

IER regimens
Yes

Abbreviations: IF: intermittent fasting, IER: intermittent energy restriction, CR: calorie restriction, VLCD: very low-calorie diet.

effects [17]. By the decrease of blood glucose after fasting,
autophagy-mediated suppression of Notch 1 signalling
occurs. Thereafter protein Ngn3 (progenitor pancreatic
cells) activation happens in pancreatic islet cells, and leads
to beta cell proliferation and neogenesis [18]. Thus, beta
cell mass and insulin secretion increase. In damaged beta
cells, this activation does not occur, and the process results
in autophagy [19].
In many animal studies using both calorie restriction
and different regimens of IF, positive effects such as
increased insulin sensitivity, improvement in lipid
parameters, weight loss, shrinkage of adipose tissue and
regression of systemic inflammation have been shown
[17,20]. Furthermore, a mouse study had shown that
the expected positive effects on beta cells were seen
additionally, and the microbiota was also found to be
improved with IF [21].
No adverse event or complication has been seen in
diabetic mice with IF in animal studies published up to
date.
4. Clinical studies on intermittent fasting and diabetes
Generally, the studies on IF and diabetes up to now have
investigated about effects on peripheral insulin resistance
and glucose homeostasis and how these effects manifested
clinically. Thus, in vitro studies have not been performed
yet.

The metabolic effects caused by IF administration in
experimental animal models have been investigated. It
has been reported that a “metabolic switch” occurs with
IF, and the activation of many pathways occurs with it
[15]. It is thought that these mechanisms of action are
also valid in humans and that beneficial metabolic effects
occur in this way. Due to low blood glucose levels during
fasting periods, less insulin secretion occurs compared to
other times [22]. In addition, insulin peaks and cortisol
release that occurs in diurnal nutrition with IF become
more suitable for the physiological pattern. These effects
contribute significantly to glucose control [23,24]. It
has also been reported that growth hormone increases
with hunger. Although it decreases when the person eats
again, it is claimed to contribute to the long-term health
protective effect [25]. Increased serum ghrelin levels and
decreased leptin concentrations have been reported in
various IF studies [24,26]. It has also been reported that
with IF, the oxygen carrying capacity increases with the
increases in erythrocyte count and haemoglobin level,
and as a result, metabolic functions improve and insulin
resistance decreases [27]. It has also been reported that
appetite is suppressed, and the feeling of satiety increases
with IF [26].
Case reports have shown that weight, blood glucose and
HbA1c control can be achieved and that IF applications
were safe with regular IF administration for 7–14 months
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in individuals with diabetes and even comorbid diseases
[28,29]. These reports noted that asymptomatic (mild)
hypoglycaemia episodes had been seen, but the patients
had been able to tolerate them and maintain IF without
suffering. The patients also had revealed that they felt
better and their life quality had improved. If we look at the
IF and type 2 DM clinical studies in summary: Arnason
et al. applied time-restricted feeding (18–20 h) for two
weeks to 10 type 2 DM patients with obesity, treated with
metformin. As a result, there was a decrease in blood
glucose and the weight of the patients at the end of the
period of IF administration, but no significant change was
found in HOMA-IR and serum lipid levels [30]. In this
short-term observational study, IF administration was
reported to be safe for diabetes because any complication,
including hypoglycaemia had not been observed. Kahleova
et al. randomized 54 obese patients with good blood
glucose control with oral antidiabetic agents into two
groups with a similar calorie intake [31]. The first group
received a diet consisting of three main meals and three
snacks, and the second group received a B2 diet for 12
weeks. As a result, the researchers found significant weight
loss and a significant decrease in hepatic adipose tissue,
blood glucose, C-peptide, fasting insulin and glucagon
levels only in the B2 group. This study did not report any
adverse event, as well.
To give a few examples of intermittent energy restriction
(IER) studies in diabetics: Carter et al. conducted a 12-week
pilot study by randomizing 63 overweight and obese type 2
DM patients to a 5:2 diet and continuous energy restriction
[26]. Eighty-one per cent of the patients completed the
study. In the 12th week, a percentage of weight loss and
a decrease in HbA1c occurred in both groups. The study
reported that 6 patients using insulin and getting IF had
hypoglycaemia and its frequency was not different from
control group. Also, it was noted that hypoglycaemia
had not repeated after insulin dose adjustment. Again,
Carter et al. randomized 137 obese type 2 DM patients
into a continuous energy restriction group and a 5:2 IER
group for 52 weeks [32]. In the study, the calorie intake
of both groups decreased by 30%. While the compliance
of the patients with their diets was over 90% in the first 3
months, it later decreased to half of that. At the end of the
study, a similar significant decrease in body weight, fasting
glucose, HbA1c and LDL-cholesterol levels was found in
both groups. These effects peaked in the third month and
then continued to decrease. A significant reduction in drug
doses was also detected in both groups. An approximate
50% reduction in insulin dose occurred in the IER group.
Most dose adjustments in the study were made within the
first three months. The more pronounced effect in these
first three months was attributed to the high number of
policlinic visits in that period. Hypo- and hyperglycaemic
events were reported to be similar in both groups in
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the first two weeks of the study (mean 3.2 vs. 5.9 event,
p = 0.28). In addition, two patients from IF group were
reported to cease participation because of headache. The
authors also published the 24-month follow-up results of
the same study [33]. They found that weight loss continued
at the end of the second year, but there was a 0.3% increase
in HbA1c. These results were similar for both groups. The
researchers commented that the increase in HbA1c is not
related to diet but is related to the course of diabetes, as
stated in previous large studies. They emphasized that the
number of antidiabetic agents used by the patients was
still less at the end of the second year compared to at the
beginning of the study. No adverse event was reported. As
a result, they stated that they showed that IER is at least as
effective as continuous energy restriction in the long term.
Corley et al. applied the 5:2 diet with the consecutive day
rule to 19 Type 2 DM patients for 12 weeks, and applied the
5:2 diet to 22 Type 2 DM patients on nonconsecutive days
[34]. Significant weight loss, a lowering of fasting blood
glucose and a decrease in HbA1c were observed in both
groups. The reduction in blood pressure was not significant.
Although the doses of antidiabetic drugs were reduced, an
increased risk of hypoglycaemia was found, similar in both
groups. However, the authors emphasized that IF is safe
in diabetic patients, since severe hypoglycaemia was not
observed. They attributed the risk of hypoglycaemia not to
the IF type but to the person’s own characteristics. Authors
emphasized that hypoglycaemia risk would be lower than
expected by instruction and drug adjustment. Any other
complication except hypoglycaemia was not reported.
Ash et al. reported that in obese diabetics, weight loss
and glucose regulation was achieved with 12-week calorie
restricted diets (IER, proportioned meals and self-selected
meals), but this was independent of diet type [35]. In
another study, three diets (five days of very low-calorie diet,
one day of very low-calorie diet and standard behavioural
diet therapy) were compared. Before the study, diabetes
medications were discontinued for two weeks, and the
patients were followed for 20 weeks. Weight loss and a
decrease in fasting glucose levels were seen in the periodic
very low-calorie diet groups. The decrease in insulin levels
and lipid levels were similar in all three groups [36]. These
studies also did not reported any adverse events.
In fact, in clinical practice, IF experience in patients
with diabetes is the most common with Ramadan fasting,
because most of the patients fast for the one month period
of Ramadan, a religious duty in Islam around the world
[4]. In a bibliometric analysis published in 2019, it was
reported that 424 articles related to diabetes and Ramadan
fasting in the 30 years between 1989–2018 were included
in the literature [37]. For this reason, organizations
such as the American Diabetes Association and the
International Diabetes Federation and many countries
have published guidelines on the management of patients
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with diabetes during Ramadan [38,39]. The point of view
of the Ramadan fast, which Muslims observe for one
month a year, should be evaluated slightly differently
from other fasts, because it is known that the majority
of Muslim diabetic patients around the world fast for at
least 15 days in Ramadan. Here, patients fast because it
is a religious obligation rather than because of the fast’s
contribution to body health or diabetes management.
Therefore, it is a correct approach to divide patients into
very high-/high-/medium-/low-risk categories in terms
of fasting and to make appropriate recommendations.
Because uncontrolled and carelessly fasting can cause a
risk for hypoglycaemia, hyperglycaemia, ketoacidosis and
thrombo-embolism. After individual evaluations, it has
been reported in many studies that patients with diabetes
can safely lose weight, improve their lipids and provide
glucose control with Ramadan fasting under conditions
when the diabetic patient is appropriately enrolled before
Ramadan, with their medication adjusted and with regular
clinical blood glucose monitoring [4,38,39].
In the articles published so far, it has been reported that
IF is generally safe for diabetic patients. It was emphasized
that people using insulin and sulfonylurea should be alert
because of the risk of hypoglycaemia [5,40]. Kahleova et
al. [31] reported that the dose of insulin, sulpfonylurea
and meglitinide should be reduced by 50% on fasting days
in patients with type 2 diabetes, an action also suggested
by Corley et al [34]. With this dose reduction, patients
should still be closely monitored for hypoglycaemia. Some
authors recommend changing the drugs according to
the HbA1c result measured before IF. According to this
recommendation, if HbA1c < 7, insulin, sulfonylurea
and meglitinide should be discontinued, and if HbA1c
is between 7 and 10, the dose should be reduced by 50%.
If it is >10, the same doses should be continued [17,40].
Although the risk of hypoglycaemia is low in the use of
metformin, thiazolidinedione, DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 analogues, one should be careful
on fasting days [16]. During IF, it is recommended that
glucose should be measured at home twice a day and that
the diet should be stopped when severe hypoglycaemia
occurs.
It should be mentioned that the IF concept and
starvation are different. However, there are claims that
if IF is performed in an uncontrolled way and for a long
time, starvation, which is a catabolic process, may occur.
In IF, since there is no frequent, long-term, excessive
calorie restriction, as IF is applied in the therapeutic sense,
symptoms seen in starvation, such as anaemia, diarrhoea,
uncontrolled weight loss and delirium, are not observed.
The number of studies on IF in pregnant women with
diabetes and on breastfeeding women are very few. These
are also Ramadan fasting studies. Although the study
results differ, generally, pregnant women (with or without

diabetes) should not be recommended any IF regimen,
including Ramadan fasting [4,16,39].
5. Our experience
Our practises are generally via as our approach on
Ramadan fasting [4]. That is, we evaluate our patients
before IF and see whether they are convenient to it. If the
patient had not poor blood glucose regulation, experiences
of hypoglycaemia or severe systemic complications, and
had good orientation, we recommend a type of IF which
he/she had adopted, under dietitian and clinician control.
After the necessary instructions are completed and
medications are adjusted, we firstly make them fast a few
times and then contact to maintain routine IF procedure.
Major part of our patient group carry out 2 days a week
16/8 diet and some of them everyday 16/8 regimen. We
usually observe weight loss, improving blood glucose
levels and lipid parameters in our patients. They do not
have hypoglycaemia as soon as they go carefully. However,
we have an important problem in our country that some of
the patients do IF according to their own orientation and
information they have got from internet and social media,
without consulting with clinician or dietician. We observe
complications like hypoglycaemia, malaise and headache
at these people much more.
6. What is the answer?
Considering animal studies, epidemiological studies,
pilot studies, clinical experiences and a small number of
randomized controlled trials conducted so far, it seems
possible to say that the beneficial effects of IF for diabetes
patients are greater than potential harms. However, there
are not yet enough studies with a high level of evidence
to recommend IF as a routine part of the treatment in
patients with diabetes. For patients who are willing to
engage in IF, especially obese diabetics, if the clinical
condition of the patient is also suitable, appropriate shortterm IF regimens can be tried under the management
of experienced physicians, nurses and dieticians. When
making a decision, individual characteristics should
be considered. Before starting IF, the patient should be
adequately trained, and medications should be adjusted.
The patient should also be followed closely with both
clinical criteria and metabolic criteria such as BMI, blood
pressure, glucose level and lipid levels. It is also necessary to
be alert to complications, such as hypoglycaemia, fatigue,
focus problems and hypotension, which may arise due to
the possibility of uncontrolled fluid and energy restriction.
It is necessary to show which IF regimen is safe and
effective, how often and for how long, for diabetic patients.
This seems possible with well-designed randomized
controlled trials focusing on long-term clinical outcomes
and eliminating confounding factors. This will make the
answer clearer.
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